Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KALM-1: Difelikefalin for Uremic Pruritus
NCT03422653Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of difelikefalin in uremic pruritus, sponsored by Cara Therapeutics, Inc.. Started Feb 2018; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT03422653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422653.